Navigation Links
New class of drug kills lymphoma cells
Date:4/14/2010

NEW YORK (April 13, 2010) -- Researchers from the Sackler Center at Weill Cornell Medical College have designed a new class of drugs that targets BCL6, a master regulatory protein responsible for causing the most common type of non-Hodgkin's lymphoma.

Findings published in today's issue of Cancer Cell show that an experimental compound designed by a team of researchers from Weill Cornell Medical College, the University of Maryland and the Ontario Cancer Center at the University of Toronto may effectively block the cancer-causing actions of BCL6 by attaching to a critical "hot spot" on its surface, thus killing off the cancer cells.

"BCL6 mediates its cancer-causing actions by attaching to other proteins," explains Dr. Ari Melnick, associate professor of medicine from the Raymond and Beverly Sackler Center for Biomedical and Physical Sciences at Weill Cornell Medical College. "Traditionally protein-protein interactions have been viewed as being too difficult to block with small-molecule drugs."

Accordingly, by observing the atomic scale structure of BCL6 attached to its partner proteins, Dr. Melnick and colleagues identified a critical "hot spot" that appeared to be amenable to designing a drug. Dr. Alexander Mackerell, from the University of Maryland, then used computational modeling to identify chemical structures that could attack this hot spot.

"We tested the ability of a large number of these chemicals to bind and block BCL6," said Dr. Melnick, "and then Dr. Gilbert Priv, from the University of Toronto, performed nuclear magnetic resonance and X-ray crystallography studies to show that a specific BCL6 inhibitor compound hit exactly in the center of the predicted hot spot. Our results show that given the right scientific approach it is quite possible to design drugs against key protein regulatory factors like BCL6."

Dr. Melnick's group showed that the BCL6 inhibitor was specific for BCL6 and did not block other master regulators, and that the experimental drug could powerfully kill DLBCL cells derived from human patients with this disease. Remarkably, the compound was completely non-toxic to animals, and could powerfully suppress and improve survival in animal models.

"This means that if given as a therapeutic agent, the compound would be unlikely to have ill-effects on healthy normal cells, and therefore would not be expected to have significant side effects," explains Dr. Melnick. "Since emerging data implicates BCL6 in other tumor types in addition to non-Hodgkin's lymphoma, it is possible that BCL6-targeted therapy could benefit many other cancer patients."

Dr. Melnick is among the physician-scientists supported by the Leukemia and Lymphoma Society's (LLS) Scholar Award Program. Since 2005, LLS has funded research in Dr. Melnick's laboratory, much of which has been focused on developing better treatments for patients with B-cell lymphomas. Dr. Melnick is also the leader of a Samuel Waxman Cancer Research Foundation Program Grant, which directly supported the effort to design small molecules for the BCL6 hot spot by the Melnick, Priv and Mackerell research team. The results of Dr. Melnick's work in this area led the LLS to form a drug discovery partnership with Forma Therapeutics to improve these drugs so they can be used in human clinical trials for hematological malignant cancers.


'/>"/>

Contact: Andrew Klein
ank2017@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Related medicine news :

1. Executive Chairman of Medifast Bradley T. MacDonald Graduates From Leadership Maryland Class of 2009
2. Abstinence-Only Classes Reduced Sexual Activity, Study Found
3. MessageSolution Unveils Enterprise Class Lotus Quickr Archiving Solution at IBM's Lotusphere 2010
4. $20,200,816.17 Settlement Fund Proposed for Blue Parking Placard Litigation to be Divided Among Class Members Who Submit a Valid Claim Form.
5. Class Action Suit Filed to Defend Rights of Children With Autism to Vital, Cost-Saving Treatment
6. David Ortiz Celebrity Golf Classic Nets More than $225,000 for Children in Need
7. Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009
8. Natural Products Association Issues Statement on DEAs Steroid Classification Action
9. Mexico City to Build World-Class Hub for Medical Research
10. A World-Class HR Master's Degree Is Now Within Reach – 100% Online
11. Hypnotist Offers $15,000 Stimulus Package to Atlanta's Middle Class to Kick Off 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest Insurance Group, ... Dallas, Miami, and Raleigh regions, is organizing an extended charity drive to benefit ... deadly chromosome abnormality. , After struggling since birth with several health challenges, T.J. ...
(Date:10/13/2017)... Pekin, IL (PRWEB) , ... October 13, 2017 ... ... Foundation, which established the certification process to promote standards of excellence for the ... iaedp™ Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at ...
(Date:10/13/2017)... ... , ... Many families have long-term insurance that covers care for a family ... for care if the client has a cognitive impairment diagnosis. , “What this ... often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, owner ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor ... on sciatica in a new episode of "Success Files," which is an award-winning ... innovation and investigates each subject in-depth with passion and integrity. , Sciatica occurs ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
Breaking Medicine News(10 mins):
(Date:10/7/2017)... , Oct. 6, 2017   Provista, a ... than $100 billion in purchasing power, today announced a ... information. The Newsroom is the online home ... trends, infographics, expert bios, news releases, slideshows and events. ... to a wealth of resources at their fingertips, viewers ...
(Date:10/4/2017)... LAWRENCE, Mass. , Oct. 4, 2017 /PRNewswire/ ... developer of single-use, self-contained, illuminating medical devices, today ... National Health Surveillance Agency (or Agência Nacional ... ®. The first single-use, cordless surgical retractor with ... ONETRAC provides optimal access, illumination and exposure of ...
(Date:10/2/2017)... Labs announces the European launch of their new low volume, high ... in Cambridge, U.K on October 4th. The ... with unprecedented speed and sensitivity while using far less sample volume ... ... ...
Breaking Medicine Technology: